These data recapitulate the continuum of change shown by Ki67 immunohistochemistry, which indicates that almost all ER-positive tumours exhibit an antiproliferative response to estrogen deprivation, although this is highly variable between patients. The gene discussed is ESR1; the disease is neoplasm.